Reading the tape
NASDAQ: LENZ
LENZ Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$290.66M
52w High
$50.40
52w Low
$8.25
P/E
-3.51
Volume
251.91K
Outstanding Shares
31.35M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -68.11%FCF (TTM): -16.94%
What changed
The stock fell 68.11% over the last year. Free cash flow declined 16.94% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Operating margin stands at -477.46%. Free cash flow fell 16.94% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.
CEOEvert Schimmelpennink
SectorHealthcare
IndustryBiotechnology
Employees6
IPO dateMar 22, 2024
Valuation
Forward P/E—
EV/EBITDA-4.79
Enterprise value$436.18M
Stock splits
Mar 22, 2024↓ Reverse
Every 7 shares became 1
Profitability & growth
Revenue growth—
Gross margin97.16%
Operating margin-477.46%
ROE-28.88%▼18.44%vs FY2024
Analyst consensus
RatingBuy
Target price$51.67▲457.39%
5
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 11, 2026
Q2 FY26 · EPS est -$1.10 · Revenue est $1.76M
View